Sarilumab

Drug Profile

Sarilumab

Alternative Names: Anti-IL 6 receptor antibody; Anti-interleukin 6 receptor antibody; Kevzara; REGN-88; SAR-153191

Latest Information Update: 25 May 2017

Price : $50

At a glance

  • Originator Regeneron Pharmaceuticals; sanofi-aventis
  • Developer Regeneron Pharmaceuticals; Sanofi
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Rheumatoid arthritis
  • Phase II Juvenile rheumatoid arthritis; Uveitis
  • Discontinued Ankylosing spondylitis

Most Recent Events

  • 22 May 2017 Registered for Rheumatoid arthritis (Combination therapy, Second-line therapy or greater) in USA (SC)
  • 22 May 2017 Registered for Rheumatoid arthritis (Monotherapy, Second-line therapy or greater) in USA (SC)
  • 22 May 2017 Efficacy and adverse event data from the phase III MOBILITY and TARGET trials in Rheumatoid arthritis released by Sanofi and Regeneron
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top